Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-22

Study Completion Date

2022-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the investigational product or placebo every day for 42 days.

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of PF-07081532 in participants with inadequately controlled type 2 diabetes mellitus, on metformin and optionally in non-diabetic participants with obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

NCT01272804

Diabetes Mellitus, Type 2 NIDDM

COMPLETED PHASE1

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

NCT01129258

Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders

COMPLETED PHASE1

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01285518

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01396187

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

NCT01469065

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-07081532

multiple dosing, once-daily for 42 days

Group Type EXPERIMENTAL

PF-07081532

Intervention Type DRUG

Study Drug, once daily for 42 days

Placebo

multiple dosing, once-daily for 42 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo, once daily for 42 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-07081532

Study Drug, once daily for 42 days

Intervention Type DRUG

Placebo

Placebo, once daily for 42 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females of non childbearing potential;
* Patients with T2DM, inadequately controlled with metformin;
* HbA1c ≥7.0% to ≤10.5% (for T2DM); HbA1c \<6.5% (for non-diabetic obese, if enrolled)
* Total body weight \>50 kg (110 lbs)
* BMI ≥24.5 to ≤45.5 kg/m2 (T2DM), BMI \>30.5 to ≤45.5 kg/m2 (for non-diabetic obese)

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, hepatic, psychiatric, neurological, dermatological, or allergic disease;
* Medical history of T2DM (for non-diabetic obese participants, if enrolled);
* Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;
* Evidence or history of clinically significant cardiovascular disease;
* Any malignancy not considered cured;
* Acute pancreatitis or history of chronic pancreatitis;
* Acute gallbladder disease;
* Any condition possibly affecting drug absorption;
* Personal or family history of MTC or MEN2;
* Medical or psychiatric condition that may increase the risk of study participation;
* Any vaccination within the 1 week prior to admission to the CRU;
* Previous administration with an investigational drug within 30 days or 5 half-lives preceding first dose;
* Known prior participation in a trial involving PF-07081532;
* A positive urine drug screen at screening or admission;
* Positive testing at screening for HIV, HBsAg, HBcAb, HBsAb or HCVAb;
* Positive COVID-19 test at screening or admission;
* Supine BP ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic);
* 12-lead ECG clinically relevant abnormalities that may affect participant safety or interpretation of study results;
* Participants with ANY of the following abnormalities in clinical laboratory tests: \*AST or ALT level ≥1.5x ULN;

* Total bilirubin level ≥1.5x ULN;
* TSH\> ULN;
* Fasting C-peptide \<0.8 ng/mL;
* Serum calcitonin \> ULN;
* Amylase \> ULN;
* Lipase \> ULN;
* eGFR \<60 mL/min/1.73m2 (per MDRD equation);
* FPG \>270 mg/dL
* History of alcohol abuse, binge drinking and/or any illicit drug use or dependence within 6 months of Screening;
* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing;
* History of sensitivity to heparin or heparin induced thrombocytopenia;
* Known intolerance to any GLP-1R agonist.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No